Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma

被引：0
|
作者：
Scognamiglio, Giosue [1 ]
Sabbatino, Francesco [2 ]
Zito Marino, Federica [1 ]
Anniciello, Anna Maria [1 ]
Cantile, Monica [1 ]
Cerrone, Margherita [1 ]
Scala, Stefania [3 ]
D'alterio, Crescenzo [3 ]
Ianaro, Angela [4 ]
Cirino, Giuseppe [4 ]
Ascierto, Paolo Antonio [5 ]
Liguori, Giuseppina [1 ]
Botti, Gerardo [1 ]
机构：
[1] Tumori Fdn G Pascale, Pathol Unit, Ist Nazl Studio & Cura, Naples, Italy
[2] Univ Salerno, Dept Med, Fac Pharm & Med, Salerno, Italy
[3] Tumori Fdn G Pascale, Mol Immunol & Immuneregulat, Ist Nazl Studio & Cura, Naples, Italy
[4] Univ Naples Federico II, Dept Pharm, Naples, Italy
[5] Tumori Fdn G Pascale, Ist Nazl Studio & Cura, Unit Med Oncol & Innovat Therapy, Naples, Italy
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2016年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
O2
引用
收藏
页数：1
相关论文
共 50 条
  • [31] COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors
    Whittle, BJR
    GUT, 2000, 47 (03) : 320 - 325
  • [32] Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
    Zhang, Xingming
    Yin, Xiaoxue
    Zhang, Haoran
    Sun, Guangxi
    Yang, Yaojing
    Chen, Junru
    Zhu, Xudong
    Zhao, Peng
    Zhao, Jinge
    Liu, Jiandong
    Chen, Ni
    Wang, Jia
    Shen, Pengfei
    Zeng, Hao
    BMC CANCER, 2019, 19 (1)
  • [33] Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
    Xingming Zhang
    Xiaoxue Yin
    Haoran Zhang
    Guangxi Sun
    Yaojing Yang
    Junru Chen
    Xudong Zhu
    Peng Zhao
    Jinge Zhao
    Jiandong Liu
    Ni Chen
    Jia Wang
    Pengfei Shen
    Hao Zeng
    BMC Cancer, 19
  • [34] PD-L1 IHC assays in melanoma
    Karim, Lina Abdul
    Wang, Peng
    Chahine, Joeffrey
    Kallakury, Bhaskar
    HISTOPATHOLOGY, 2017, 70 (07) : 1177 - 1179
  • [35] PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma
    Chae, H.
    Kim, J. E.
    Kim, W.
    Lee, J-S.
    Song, S. Y.
    Lee, M. H.
    Chung, H. W.
    Song, J. S.
    Ahn, J-H.
    ANNALS OF ONCOLOGY, 2019, 30 : 702 - 702
  • [36] Regulation of PD-L1 in uveal melanoma
    Souri, Zahra
    Wierenga, Annemijn Philine Annette
    Spruyt-Gerritse, Marijke
    Eikmans, Michael
    Jager, Martine J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [37] PD-L1 in melanoma: facts and myths
    Mandala, Mario
    Merelli, Barbara
    Massi, Daniela
    MELANOMA MANAGEMENT, 2016, 3 (03) : 187 - 194
  • [38] A Focus on PD-L1 in Human Melanoma
    Hersey, Peter
    Gallagher, Stuart
    CLINICAL CANCER RESEARCH, 2013, 19 (03) : 514 - 516
  • [39] The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic Targets
    Al-Diabat, Muhsen
    Ayoub, Nehad M.
    Eitan, Laith A. L.
    Alshorman, Moath
    Shatnawi, Aymen
    CURRENT CANCER DRUG TARGETS, 2024,
  • [40] Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma.
    Javed, Asad
    Arguello, David
    Johnston, Curtis
    Gatalica, Zoran
    Orloff, Mariana M.
    Mastrangelo, Michael J.
    Sato, Takami
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345